Effect of supplementation in treatment of patients with polycystic ovary syndrome

Clinical trial of the effect of vitamin D supplementation compared with the placebo on gene expression related to insulin, inflammation and lipid in patients with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201701025623N99

Enrollment

Registered

2017-01-06

Start date

2016-12-12

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovarian syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: 50000 IU vitamin D (Zahravi, Tabriz, Iran), once every 2 weeks, for 12 weeks orally. Intervention 2: Control group: Placebo (Barij Essence, Kashan, Iran), once ever

Treatment - Drugs

Intervention group: 50000 IU vitamin D (Zahravi, Tabriz, Iran), once every 2 weeks, for 12 weeks orally.

Control group: Placebo (Barij Essence, Kashan, Iran), once every 2 weeks, for 12 weeks orally.

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with polycystic ovary syndrome; aged 18 to 40 years. Exclusion criteria: Unwillingness to cooperate.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Expressed levels of PPAR-?. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: PCR.;Expressed levels of GLUT-1. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: PCR.	—

Secondary

Measure	Time frame
Expressed levels of LL-1 gene. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: PCR.;Expressed levels of LL-8 gene. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: PCR.;Expressed levels of TNF-a gene. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: PCR.;Expressed levels of ox-LDL gene. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: PCR.	—

Measure

Time frame

Expressed levels of LL-1 gene. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: PCR.;Expressed levels of LL-8 gene. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: PCR.;Expressed levels of TNF-a gene. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: PCR.;Expressed levels of ox-LDL gene. Timepoint: At the beginning of the study and 12 weeks after intervention. Method of measurement: PCR.

—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026